Omalizumab
- PDF / 170,241 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 117 Downloads / 201 Views
1
Omalizumab Omalizumab allergy, significant of maculopapular drug eruption: case report A 65-year-old woman developed drug-allergy, significant of maculopapular eruption, during treatment with omalizumab for severe asthma. The woman had a medical history of allergic rhinitis, gastroesophageal reflux disease and asthma since childhood. Upon exertion, she would develop dyspnoea, which was refractory to high-dose inhaled corticosteroids, long-acting beta agonists and long acting muscarinic antagonist. She would frequently require short-term oral corticosteroid treatment for her asthma; however, she still had frequent exacerbations of asthma. Additionally, she had also developed hypercapnic respiratory failure in the previous 3 years, requiring mechanical ventilation support six times. In March 2017, she was referred for her asthma, for which she started receiving famotidine, theophylline and montelukast. Detailed investigations revealed uncontrolled status of her severe asthma, for which she was initiated on SC injections of omalizumab 150mg for 3 months. However, 2 weeks after receiving fourth injection of omalizumab, she small pruritic erythematous papules over her extremities and trunk. Drug eruption was considered based on the high Naranjo score. A biopsy was conducted, and the results were suggestive of maculopapular drug eruption. The woman underwent omalizumab desensitization smoothely on 19 September and 3 October. During following few months, she remained stable, and the skin rash resolved one month after receiving last dose of omalizumab. Later, in May 2018, she developed Moraxella atarrhalis pneumonia. Subsequently, in August 2018, due to presence of IgE over airway epithelium cells, she again received omalizumab at the dose of 300mg. She continued to take treatment with omalizumab with better control over her asthma. Kuo C-W, et al. Bronchoscopy-guided bronchial epithelium sampling as a tool for selecting the optimal biologic treatment in a patient with severe asthma: A case report. Allergy, Asthma and Clinical Immunology 15: No. 1, 27 Nov 2019. Available from: URL: http://doi.org/10.1186/s13223-019-0378-6 803443608 Taiwan
0114-9954/20/1785-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 4 Jan 2020 No. 1785
Data Loading...
